Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 open-label study of E/C/F/TAF single-tablet regimen in HIV-1 infected adolescents
2013-002780-26Phase 2
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: Safety and tolerability through Week 48 in Cohort 1 Part A.
02
Drugs
elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2013-002780-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002780-26.